ArticleFrontiers in microbiology2026
Epidemiological characteristics and whole-genome analysis of respiratory syncytial virus in Jining city from February 2023 to December 2024.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine learning based development of an early diagnosis signature for distinguishing hospitalized pediatric human respiratory syncytial virus infection from mycoplasma pneumonia.Frontiers in pediatrics · 2026Article
- Epidemiological characteristics and genetic evolution of rhinovirus in Jining City, 2024-2025.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory syncytial virus (RSV) is a major viral pathogen causing respiratory tract infections in children, often leading to bronchiolitis, pneumonia, and even death. This study aimed to investigate the epidemiological patterns and whole-genome characteristics of RSV circulating in Jining city between February 2023 and December 2024. Methods: From February 2023 to December 2024, a total of 5,042 throat swab samples were collected from influenza-like illness (ILI) cases at two sentinel hospitals in Jining. RSV was detected using reverse transcription quantitative real-time PCR (RT-qPCR). RSV-positive samples were subjected to whole-genome sequencing. Phylogenetic trees were constructed based on the whole genome and G gene sequences, and antigenic variation in viral proteins was analyzed. Results: RSV positivity was 1.98% (100/5042), with higher rates in children under 5 years of age. RSV activity peaked in April-May 2023 and December 2023-January 2024. A total of 29 RSV genomes were sequenced, including 18 RSV-A and 11 RSV-B. RSV-A was dominant during the first peak, and RSV-B during the second. Most RSV-A strains belonged to clade AD.3 and genotype ON1; RSV-B strains clustered into clades B.D.E.1, B.D.4.1.1, and B.D.E.2, all within genotype BA9. Mutations were identified in antigenic epitopes of the G and F proteins, including amino acid substitutions and changes in glycosylation and phosphorylation sites. Conclusion: RSV-A and RSV-B circulated in Jining in an alternating pattern, with evidence of ongoing antigenic evolution. Continued RSV surveillance and accelerated vaccine development are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.